Amy M. DeLozier

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial

Daniel J. Wallace, Richard Furie, Yoshiya Tanaka et al. · The Lancet · 2018 · 497 citations · Full text

Systemic Lupus Erythematosus, Systemic Lupus Erythematosus Treatment, Lupus +8

Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase<scp>III</scp>trials

Eric L. Simpson, J.‐P. Lacour, Lynda Spelman et al. · British Journal of Dermatology · 2020 · 363 citations

Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study

Emma Guttman‐Yassky, Jonathan I. Silverberg, Osamu Nemoto et al. · Journal of the American Academy of Dermatology · 2018 · 304 citations

Drug Hypersensitivity, Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis +8

Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis

Kristian Reich, Kenji Kabashima, Ketty Peris et al. · JAMA Dermatology · 2020 · 267 citations · Full text

Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative)

Joanne R Chalmers, Kim S Thomas, Christian Apfelbacher et al. · British Journal of Dermatology · 2018 · 160 citations · Full text